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1. INTRODUCTION {#hsr2109-sec-0006}
===============

Sarcoidosis is a systemic disease of unknown cause that can affect many organs but that most frequently (90%‐95% of cases) affects the lungs.[1](#hsr2109-bib-0001){ref-type="ref"} Together, sarcoidosis and idiopathic pulmonary fibrosis represent the two most common etiologies of interstitial lung disease.[1](#hsr2109-bib-0001){ref-type="ref"}

Histologically, sarcoidosis is characterized by the formation of epithelioid and giant cell granulomas without caseous necrosis,[2](#hsr2109-bib-0002){ref-type="ref"} and it is usually classified in five stages based on radiological findings. Stage IV corresponds to the chronic fibrosing form of the disease, which accounts for approximately 5.4% of pulmonary sarcoidosis cases.[3](#hsr2109-bib-0003){ref-type="ref"} Patients with chronic respiratory diseases often display disabling dyspnea associated with a progressive reduction in daily life physical activity (DL~PA~), as has previously been demonstrated in patients with interstitial lung diseases, including idiopathic pulmonary fibrosis.[4](#hsr2109-bib-0004){ref-type="ref"} Reduced physical activity is an important clinical parameter related to increased morbidity, mortality, and hospitalizations in many chronic diseases.[5](#hsr2109-bib-0005){ref-type="ref"}

Little is known about DL~PA~ in patients with chronic sarcoidosis.[6](#hsr2109-bib-0006){ref-type="ref"}, [7](#hsr2109-bib-0007){ref-type="ref"}, [8](#hsr2109-bib-0008){ref-type="ref"}, [9](#hsr2109-bib-0009){ref-type="ref"} Saligan showed a reduction in physical activity associated with fatigue, depressive symptoms, and a shorter distance in the 6‐minute walk test (6MWT),[9](#hsr2109-bib-0009){ref-type="ref"} whereas Bahmer et al found a significant association with 6MWT distance and quality of life scores but only a weak association with fatigue.[6](#hsr2109-bib-0006){ref-type="ref"} However, these studies examined patients with a variety of respiratory conditions, and relatively few of them had chronic fibrotic disease. With this in mind, we sought to quantify DL~PA~ in patients with stage IV chronic sarcoidosis and determine the relationships between two‐defined DL~PA~ parameters and a number of pulmonary function, aerobic capacity, and quality of life measures. The main objective of this work was to evaluate DL~PA~ in patients with chronic stage IV sarcoidosis compared with healthy control subjects. The secondary objective was to determine the factors associated with DL~PA~ in patients with chronic sarcoidosis.

2. METHODS {#hsr2109-sec-0007}
==========

2.1. Patients {#hsr2109-sec-0008}
-------------

Fifty‐three patients with stage IV chronic sarcoidosis[10](#hsr2109-bib-0010){ref-type="ref"} were enrolled in the study. Of these, 29 were part of the National PHRC 2012‐A00347‐36 "Respiratory rehabilitation in chronic fibrotic sarcoidosis (stage IV): a randomized therapeutic trial" ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT02044939), and 24 consecutive patients were referred by their pulmonologists in the North of France to our Center for Rare Pulmonary Diseases for prerehabilitation assessment. Inclusion criteria were: (1) a sarcoidosis diagnosis according to the American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) statement[10](#hsr2109-bib-0010){ref-type="ref"} and (2) radiographic stage IV disease defined by patent advanced fibrosis with evidence of upper lobe volume loss with hilar retraction with or without masses, coarse linear bands, honeycombing, bullae, and emphysema. In addition, we enrolled 28 healthy volunteers who were students or relatives of employees at the hospital. The controls were selected to be comparable in age and sex ratio. All control subjects had normal spirometry results. None of the patients or control subjects was engaged in exercise training programs prior to the study. All individuals gave informed consent, and approval for the use of the data was provided by the Institutional Review Board of the French Learned Society for Pulmonology (CEPRO 2017‐007).

2.2. Assessment of daily life physical activity {#hsr2109-sec-0009}
-----------------------------------------------

Subjects were equipped with a physical activity monitor (SenseWear Pro armband and SenseWear software version 8.0; BodyMedia Inc., Pittsburgh, Pennsylvania, United States) and instructed to wear the device continuously, except while showering or bathing, for five consecutive days (three weekdays and two weekend days). The device was positioned on the upper right arm at the midpoint between the acromion and the olecranon, as previously described.[11](#hsr2109-bib-0011){ref-type="ref"} DL~PA~ was assessed by measuring the number of steps per day (SPD) and the total daily energy expenditure (TEE, in kcal/day). All functional tests and questionnaires were performed on the same day, prior to the 5‐day DL~PA~ monitoring.

2.3. Pulmonary function tests {#hsr2109-sec-0010}
-----------------------------

Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV~1~), and total lung capacity (TLC) were measured by spirometry and plethysmography with a Jaeger‐Masterlab cabin (Vyaire Medical, Hoechberg, Germany), and single‐breath diffusing capacity of the lung for carbon monoxide (DLco, in mL CO/min/mmHg) was measured and corrected for hemoglobin concentration. Reference equations for lung volumes and DLco were taken from ERS.[12](#hsr2109-bib-0012){ref-type="ref"}, [13](#hsr2109-bib-0013){ref-type="ref"} The lower limits of "normal" were set at the fifth percentile (or predicted minus 1.64 standard deviations \[SD\]) of each reference population, according to the 2005 ATS/ERS guidelines.[14](#hsr2109-bib-0014){ref-type="ref"} The results are conventionally expressed as percent of the predicted values.

2.4. Six‐minute walk test (6MWT) {#hsr2109-sec-0011}
--------------------------------

The 6MWT was performed in accordance with international recommendations[15](#hsr2109-bib-0015){ref-type="ref"} using a 30‐m indoor corridor in our hospital. Two 6MWT were performed and the results of the second ISWT were recorded for analysis. Pulse O~2~ saturation (SpO~2~) and heart rate were monitored continuously using a Novametrix 513 Pulse Oximeter (Wallingford, Connecticut, United States).

2.5. Cardiopulmonary exercise test {#hsr2109-sec-0012}
----------------------------------

Subjects completed a triangular exercise test on a cycle ergometer (Ergometrics 800; Ergoline, Bitz, Germany), with blood pressure and electrocardiographic monitoring (Medcard; Medisoft, Sorrine, Belgium) according to a standardized protocol, as detailed previously.[16](#hsr2109-bib-0016){ref-type="ref"} We focused on aerobic capacity assessed by maximal oxygen uptake (VO~2~max), and the results are expressed as mL O~2~/kg/min and the percentage of predicted values.[17](#hsr2109-bib-0017){ref-type="ref"}

2.6. Dyspnea {#hsr2109-sec-0013}
------------

Dyspnea occurring during the patients\' daily lives was assessed using the modified Medical Research Council (mMRC) self‐administered questionnaire, which consists of five questions about perceived breathlessness and is scored on a scale from 0 (not troubled by breathlessness except during strenuous exercise) to 4 (very severe dyspnea: too breathless to leave the house or breathless when dressing or undressing).[18](#hsr2109-bib-0018){ref-type="ref"}

2.7. Fatigue {#hsr2109-sec-0014}
------------

Fatigue occurring during the patients\' daily lives was assessed using the Fatigue Assessment Scale (FAS) questionnaire, in which a score greater than 22 (on a scale of 10‐50) is considered clinically significant.[19](#hsr2109-bib-0019){ref-type="ref"}

2.8. Quality of life {#hsr2109-sec-0015}
--------------------

The patients indicated their overall quality of life using the Visual Simplified Respiratory Questionnaire (VSRQ). A score of at least 80 (on a scale of 0‐100) indicates a satisfactory quality of life.[20](#hsr2109-bib-0020){ref-type="ref"}

2.9. Anxiety and depression {#hsr2109-sec-0016}
---------------------------

The Hospital Anxiety and Depression Scale (HADS) was designed to identify and quantify the two most common forms of psychological disorders in medical patients.[21](#hsr2109-bib-0021){ref-type="ref"} For both subscales, a score of 8 to 10 (on a scale of 0‐21) is indicative of uncertain symptoms, and a score greater than 11 is indicative of clinically relevant symptoms.

2.10. Statistical analysis {#hsr2109-sec-0017}
--------------------------

Continuous variables are expressed as means (SD) for normally distributed data and medians (interquartile range \[IQR\]) for other data. Categorical variables are expressed as numbers (percentage). Normality of distribution was assessed visually using histograms and statistically using the Shapiro--Wilk test. Patient characteristics were compared with those of healthy control subjects using student\'s *t* test for quantitative variables and Chi‐square test for sex. DL~PA~ parameters were compared between patients and control subjects using an analysis of variance. Comparisons were further adjusted for prespecified confounding factors (age, body mass index \[BMI\], and sex) using multivariable linear regression models. For the patient group, correlations between each DL~PA~ parameter were assessed by calculating Pearson\'s correlation coefficients (r) with 95% confidence intervals (95%CIs) calculated using Fisher\'s Z transformation. Associations between DL~PA~ parameters and patient characteristics (continuous variables) were first assessed in univariable analyses by calculating Pearson\'s correlation coefficients. Significant characteristics (*P* \< 0.1) were then entered into a forward‐stepwise multivariable linear regression analysis by including prespecified confounding factors (age, BMI, and sex) as forced variables. Colinearity between candidate factors in the multivariable analysis was examined by calculating variance inflation factors using an alert threshold value of 2.5.[22](#hsr2109-bib-0022){ref-type="ref"} Finally, the selected multivariable model was further adjusted for the prespecified confounding factors (age, BMI, and sex). Statistical testing was done at the two‐tailed *α* level of 0.05. Data were analyzed using SAS software version 9.4 (SAS Institute, Cary, North Carolina, United States).

3. RESULTS {#hsr2109-sec-0018}
==========

The characteristics of the patients with sarcoidosis and healthy control subjects are summarized in Tables [1](#hsr2109-tbl-0001){ref-type="table"} and Table [2](#hsr2109-tbl-0002){ref-type="table"}. Pulmonary function tests showed that DLco was reduced (\<80% predicted) in 46 of the 53 (87%) patients with sarcoidosis. A restrictive pattern (TLC \< 80% predicted) was observed in 20 patients (38%), and an obstructive pattern (FEV~1~/FVC \< 70%) was seen in 31 patients (58%). Twenty‐two patients (41%) displayed significant fatigue (FAS score \> 22), 14 (26%) had a significant HADS anxiety score (≥11), and 11 (20%) had a significant HADS depression score (≥11). Most of the patients (75.5%) were treated with steroids (mean daily dose 11.3 mg/day); of these, 45.3% were also taking additional immunosuppressive drugs.

###### 

Characteristics of patients with sarcoidosis and healthy controls

  Characteristic                                                 Patients with Sarcoidosis   Healthy Controls   *P* Value
  -------------------------------------------------------------- --------------------------- ------------------ ------------------------------------------------
  Age (years) (mean \[SD\])                                      59.2 (9.4)                  57.1 (9.4)         0.35[a](#hsr2109-note-0001){ref-type="fn"}
  BMI (kg/m^2^) (mean \[SD\])                                    28.1 (6.6)                  23.8 (2.7)         \< 0.001[a](#hsr2109-note-0001){ref-type="fn"}
  Women (n \[%\])                                                24.0 (47.3)                 16.0 (57.1)        0.31[b](#hsr2109-note-0002){ref-type="fn"}
  Patients taking prednisone (n \[%\])                           40.0 (75.5)                 ‐                  ‐
  Prednisone dose (mg/day) (mean \[SD\])                         11.3 (11.2)                 ‐                  ‐
  Patients taking additional immunosuppressant drugs (n \[%\])   24.0 (45.3)                 ‐                  ‐

Calculated using student\'s *t* test.

Calculated using Chi‐square test. BMI: body mass index; SD: standard deviation.

###### 

Functional characteristics of the 53 patients with sarcoidosis

                           Values        
  ------------------------ ------------- -------------------
  FEV~1~ (L)               1.8 (0.7)     1.7 (1.3, 2.2)
  FEV~1~ (% predicted)     63.5 (19.6)   61.0 (51.0, 72.0)
  TLC (L)                  5.0 (1.5)     4.9 (4.0, 5.8)
  TLC (% predicted)        83.2 (18.6)   84.0 (71.0, 93.0)
  FVC (L)                  2.8 (1.0)     2.5 (2.1, 3.4)
  FVC (% predicted)        79.4 (19.5)   75.0 (66.0, 96.0)
  FEV~1~/FVC (%)           80.6 (16.4)   80.6 (69.6, 96.8)
  DL~CO~ (mL/min/mmHg)     12.3 (6.2)    11.2 (7.1, 16.7)
  DL~CO~ (% predicted)     55.7 (18.4)   57.0 (42.0, 65.0)
  6MWT distance (m)        423 (115)     441 (360, 490)
  6MWT nadir SpO~2~ (%)    90.2 (6.1)    92.0 (89.0, 95.0)
  VO~2~max (mL/kg/min)     17.6 (5.7)    15.5 (13.9, 21.5)
  VO~2~max (% predicted)   71.3 (18.1)   69.0 (61.5, 80.5)
  VSRQ score               41.7 (16.4)   40.5 (31.0, 54.5)
  HADS anxiety score       8.2 (4.0)     7.5 (5.0, 10.5)
  HADS depression score    6.8 (4.0)     6.5 (4.0, 9.5)
  mMRC score               2.0 (1.0)     2.0 (1.0, 3.0)
  FAS score                26.2 (6.6)    26.0 (22.0, 29.0)

Abbreviations: 6MWT: 6‐minute walk test; DLco: diffusing capacity for carbon monoxide; FAS: Fatigue Assessment Score; FEV~1~: forced expiratory volume in 1 second; FVC: forced vital capacity; VSRQ: Visual Simplified Respiratory Questionnaire; HADS: Hospital Anxiety and Depression Scale; mMRC: modified Medical Research Council questionnaire; SD: standard deviation; TLC: total lung capacity; IQR: interquartile range.

The DL~PA~ parameters for patients with sarcoidosis and control subjects are shown in Table [3](#hsr2109-tbl-0003){ref-type="table"} and Figure [1](#hsr2109-fig-0001){ref-type="fig"}. Patients walked significantly fewer SPD than did the control subjects (6395 ± 4119 and 11 817 ± 3600, respectively; *P* \< 0.001 after adjustment for age, BMI, and sex in a multivariable linear regression model). No statistically significant difference was observed for TEE between patients with sarcoidosis and healthy controls (median \[IQR\] 2369 \[2004‐2827\] vs 2387 \[2319‐2876\] kcal/day, respectively; *P* = 0.054 after adjustment for age, BMI, and sex in a multivariable linear regression model). There was a moderate correlation between the DL~PA~ parameters (Pearson\'s correlation \[r\] = 0.49, 95%CI = 0.25, 0.67; *P* \< 0.001). In addition, the time (min/day) spent in activities with an estimated energy expenditure of greater than 2.5 metabolic equivalents (METs) and the total energy expenditure greater than 2.5 METs (kcal/day) were significantly lower in patients than in controls ([Supplementary table 1](#hsr2109-supitem-0001){ref-type="supplementary-material"}).

###### 

Daily life physical activity (DL~PA~) parameters in patients with sarcoidosis and healthy control subjects

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                             Patients with Sarcoidosis N = 53   Healthy Controls N = 28   *P* Value[a](#hsr2109-note-0004){ref-type="fn"}   Adjusted\
                                                                                                                                                                       *P* Value[b](#hsr2109-note-0005){ref-type="fn"}
  ----------------------------------------------------- ---------------------------------- ------------------------- ------------------------------------------------- -------------------------------------------------
  Number of steps per day (mean \[SD\])                 6395 (4119)                        11 817 (3600)             \<0.001                                           \<0.001

  Total energy expenditure, kcal/day (median \[IQR\])   2369 (2004, 2827)                  2387 (2319, 2876)         0.14[c](#hsr2109-note-0006){ref-type="fn"}        0.054[c](#hsr2109-note-0006){ref-type="fn"}

                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Calculated using student\'s *t* test.

Calculated using multivariable linear regression analysis adjusted for age, sex, and body mass index (BMI).

After log transformation. IQR: interquartile range; SD: standard deviation.

![Physical activity in daily life for patients with sarcoidosis and healthy controls (A) Number of steps per day and (B) total daily energy expenditure in healthy controls (n = 28) and patients with chronic sarcoidosis (n = 53). Lines indicate mean. Differences were analyzed using student\'s *t* test.](HSR2-2-e109-g001){#hsr2109-fig-0001}

Table [4](#hsr2109-tbl-0004){ref-type="table"} shows the correlations between DL~PA~ parameters and pulmonary function tests, exercise tests, self‐reported questionnaires, and the main characteristics of the patients with sarcoidosis. Oral steroids did not influence the DL~PA~ parameters (data not shown). In univariable analysis, SPD was positively correlated with 6MWT distance (*r* = 0.32, 95%CI = 0.06, 0.55; *P* = 0.019), VO~2~max (*r* = 0.44, 95%CI = 0.17, 0.65; *P* = 0.002), and VSRQ score (*r* = 0.44, 95%CI = 0.19, 0.64; *P* = 0.001), and negatively correlated with mMRC score (*r* = −0.38, 95%CI = −0.60, −0.10; *P* = 0.009). In multivariable analysis, only VO~2~max remained significantly associated with SPD (*P* = 0.012 after adjustment for age, BMI, and sex in a multivariable linear regression model; Table [5](#hsr2109-tbl-0005){ref-type="table"}). TEE was positively correlated with BMI (*r* = 0.38, 95%CI = 0.13, 0.59; *P* = 0.004), FEV~1~ (*r* = 0.55, 95%CI = 0.33, 0.71; *P* \< 0.001), TLC (*r* = 0.44, 95%CI = 0.18, 0.64; *P* = 0.001), and FVC (*r* = 0.56, 95%CI = 0.34, 0.72; *P* \< 0.001) in univariable analysis. Since the difference in TEE was considered not to be clinically significant, the multivariable analysis were not performed.

###### 

Correlations between daily life physical activity (DL~PA~) parameters and characteristics in the patients with sarcoidosis (n = 53)

  Characteristic                                          Number of Steps Per Day   Total Energy Expenditure (kcal/day)[a](#hsr2109-note-0007){ref-type="fn"}                          
  ------------------------------------------------------- ------------------------- --------------------------------------------------------------------------- ---------------------- ---------
  Age                                                     −0.21 (−0.45, 0.06)       0.13                                                                        −0.06 (−0.32, 0.22)    0.69
  BMI                                                     −0.10 (−0.36, 0.17)       0.47                                                                        0.38 (0.13, 0.59)      0.004
  Prednisone dose[c](#hsr2109-note-0009){ref-type="fn"}   −0.22 (−0.46, 0.05)       0.11                                                                        −0.13 (−0.39, 0.14)    0.34
  FEV~1~                                                  0.23 (−0.04, 0.47)        0.096                                                                       0.55 (0.33, 0.71)      \<0.001
  FVC                                                     0.26 (−0.01, 0.50)        0.056                                                                       0.56 (0.34, 0.72)      \<0.001
  FEV~1~/FVC                                              −0.04 (−0.31, 0.23)       0.77                                                                        0.05 (−0.22, 0.32)     0.71
  TLC                                                     0.21 (−0.07, 0.46)        0.14                                                                        0.44 (0.18, 0.64)      0.001
  DLco                                                    −0.05 (−0.33, 0.22)       0.69                                                                        0.18 (−0.10, 0.44)     0.21
  VO~2~max                                                0.44 (0.17, 0.65)         0.002                                                                       0.04 (−0.25, 0.33)     0.77
  6MWT distance                                           0.32 (0.06, 0.55)         0.019                                                                       0.14 (−0.14, 0.39)     0.33
  6MWT nadir SpO~2~                                       0.27 (−0.004, 0.50)       0.053                                                                       0.17 (−0.11, 0.43)     0.22
  mMRC score                                              −0.38 (−0.60, −0.10)      0.009                                                                       −0.13 (−0.40, 0.16)    0.37
  HADS score, depression                                  −0.19 (−0.44, 0.08)       0.17                                                                        −0.01 (−0.28, 0.26)    0.95
  HADS score, anxiety                                     −0.004 (−0.28, 0.27)      0.97                                                                        −0.007 (−0.27, 0.28)   0.96
  FAS score                                               0.11 (−0.21, 0.40)        0.49                                                                        0.09 (−0.23, 0.38)     0.59
  VSRQ score                                              0.44 (0.19, 0.64)         0.001                                                                       −0.007 (−0.28, 0.27)   0.96

After log transformation.

Pearson\'s correlation coefficient.

Dose in mg/day.

Abbreviations: 6MWT: 6‐minute walk test; BMI: body mass index; CI: confidence interval; DLco: diffusing capacity for carbon monoxide; FAS: Fatigue Assessment Score; FEV~1~: forced expiratory volume in 1 second; FVC: forced vital capacity; HADS: Hospital Anxiety and Depression Scale; mMRC: modified Medical Research Council questionnaire; TLC: total lung capacity; VSRQ: Visual Simplified Respiratory Questionnaire.

###### 

Final model of factors affecting the number of steps per day in patients with sarcoidosis after adjustment for age, sex, and body mass index (BMI)

  Parameters and Factors    Estimate[a](#hsr2109-note-0011){ref-type="fn"}   SE[a](#hsr2109-note-0011){ref-type="fn"}   Partial *R* ^*2*^ (%)[a](#hsr2109-note-0011){ref-type="fn"}   *P* Value[a](#hsr2109-note-0011){ref-type="fn"}
  ------------------------- ------------------------------------------------ ------------------------------------------ ------------------------------------------------------------- -------------------------------------------------
  Number of steps per day                                                                                               13.3                                                          
  VO~2~max                  314                                              120                                                                                                      0.012
  Age                       −47.7                                            61.8                                                                                                     0.44
  Sex (men vs women)        −221                                             1285                                                                                                     0.86
  BMI                       28.2                                             101                                                                                                      0.78

All variables associated with number of steps per day in the univariable analyses (at *P* \< 0.10) were considered as candidate variables for multivariable analysis. The multivariable analysis was conducted using a forward‐stepwise selection approach, as specified in the statistical analysis section, by including pre‐specified confounders as forced variables (age, BMI, and sex).

4. DISCUSSION {#hsr2109-sec-0019}
=============

The results of this study show that DL~PA~ is decreased in adult patients with stage IV sarcoidosis and that SPD is significantly associated with VO~2~max. Our results are in agreement with three previous studies evaluating physical activity in patients with sarcoidosis.[6](#hsr2109-bib-0006){ref-type="ref"}, [7](#hsr2109-bib-0007){ref-type="ref"}, [8](#hsr2109-bib-0008){ref-type="ref"} Kostorz et al[7](#hsr2109-bib-0007){ref-type="ref"} evaluated the comorbidities associated with DL~PA~ in 30 patients with sarcoidosis, albeit without precise radiological staging and found that the patients had walked a mean (±SD) SPD of 5214 (±2699). Pilzak et al found that patients with sarcoidosis not only showed low mean SPD (4566 ± 2378) but also displayed reduced exercise tolerance, as measured by the VO~2~max and 6MWT.[8](#hsr2109-bib-0008){ref-type="ref"} However, that study did not examine correlations between DL~PA~ and pulmonary function, exercise tolerance, or mood parameters (anxiety and depression). In our study, multivariable analysis showed no correlation between SPD and resting functional parameters (DLco, FEV~1~, TLC, and FVC), and a correlation between SPD and exercise tolerance was detected only when the latter was evaluated by VO~2~max but not by the 6MWT. Finally, the study by Bahmer et al showed an association between SPD and 6MWT distance, fatigue score (Multidimensional Fatigue Inventory), and quality of life scores (St. George\'s Respiratory and SF‐12 questionnaires).[6](#hsr2109-bib-0006){ref-type="ref"} However, it is important to note that Bahmer et al included only three patients with chronic sarcoidosis stage IV in their study cohort, which could explain the differences between their and our results. Indeed, the mean (±SD) SPD recorded in that study (7490 ± 3007)[6](#hsr2109-bib-0006){ref-type="ref"} was higher than in our study (6395 ± 4119).

Our data suggest that submaximal stress tests are insufficient to evaluate the mechanisms underlying the reduced DL~PA~ in patients with sarcoidosis. To our knowledge, only one study has previously evaluated parameters other than SPD to quantify DL~PA~ in patients with chronic sarcoidosis.[7](#hsr2109-bib-0007){ref-type="ref"} Although daily energy expenditure was also associated with VO~2~max in that study, only patients with less severe disease (stage II) were evaluated.[7](#hsr2109-bib-0007){ref-type="ref"} We also found that total daily expenditure was correlated with FEV~1~. Bahmer et al[6](#hsr2109-bib-0006){ref-type="ref"} found that FEV~1~ was associated with the 6MWT distance but not with SPD in patients with sarcoidosis. However, the mean FEV~1~ in that study was less severe than in our study. Similar findings to ours have been reported in patients with chronic obstructive pulmonary disease, who display a progressive decrease in FEV~1~ that is paralleled by a decrease in physical activity.[23](#hsr2109-bib-0023){ref-type="ref"} Our study is the first to show that the obstructive ventilatory defect is correlated with DL~PA~ in patients with sarcoidosis and might explain part of the reduction in daily TEE. Interestingly, both the pulmonary function pattern and the high percentage of patients with an obstructive ventilatory defect in our cohort are similar to those reported by Nardi et al, who examined a large group of patients with stage IV sarcoidosis.[24](#hsr2109-bib-0024){ref-type="ref"}

Although patients with sarcoidosis commonly show fatigue[25](#hsr2109-bib-0025){ref-type="ref"} associated with both a poor quality of life[26](#hsr2109-bib-0026){ref-type="ref"} and a shorter 6MWT distance,[6](#hsr2109-bib-0006){ref-type="ref"}, [27](#hsr2109-bib-0027){ref-type="ref"} we did not find a relationship between fatigue and DL~PA~ in our study~.~ We also did not observe an association between DL~PA~ and either anxiety or depression scores, which, to our knowledge, is an observation not previously reported for patients with sarcoidosis. Our finding of only weak/moderate associations between DL~PA~ parameters and quality of life contrasts with the studies of Bahmer et al[6](#hsr2109-bib-0006){ref-type="ref"} and Baughman et al,[28](#hsr2109-bib-0028){ref-type="ref"} who found strong correlations between the St George\'s Respiratory Questionnaire (SGRQ) score and the SPD and 6MWT distance, respectively. The altered quality of life in patients with sarcoidosis could well be a consequence and not a causal determinant of the limitation of DL~PA.~ Indeed, one can hypothesize that functional impairment (ie, FEV~1~ and VO~2~max) is more important than fatigue in explaining limitations of DL~PA~ and low quality of life in patients with sarcoidosis. Nevertheless, it is important to note that VSRQ and SGRQ are not routinely used to assess patients with sarcoidosis, so these tools may be insufficiently specific to evaluate quality of life in our population.

Only a fraction of the reduction in DL~PA~ in patients with sarcoidosis could be explained by the resting and exercise functional parameters examined here, suggesting that it may be important to investigate the influence of environmental and sociodemographic factors in future studies. In support of this, a study of patients with chronic obstructive pulmonary disease found that dog ownership or having small children was significantly associated with time spent in moderate to sustained physical activities (3‐6 metabolic equivalents).[29](#hsr2109-bib-0029){ref-type="ref"} Place of residence and psychological factors also seem to be important influences on the level of physical activity. Sallis et al found an association between daily physical activity in healthy adults, as measured by an accelerometer and the density of neighborhood parks and public transport.[30](#hsr2109-bib-0030){ref-type="ref"} However, there have been no comparable studies in patients with respiratory diseases. Bauman et al reviewed 16 articles on healthy adults with a history of physical activity during adolescence and adulthood, and they found that self‐efficacy (confidence in the ability to be active in specific situations) is the most important determinant of physical activity.[31](#hsr2109-bib-0031){ref-type="ref"} These different sociodemographic elements must be studied in various patient populations to determine their relevance to each specific respiratory disease and their contributions to interindividual variability in DL~PA~.

In addition to the limitations inherent to the observational exploratory design, our study has several weaknesses. There was no formal sample size calculation, so we cannot exclude the possibility that differences may have been overlooked because of inadequate statistical power. In a posterior power calculation, the smallest significant difference that our sample size (53 patients with sarcoidosis and 28 healthy controls) allowed us to detect with 80% power was 0.7 (standardized mean difference), which is interpreted as a large effect size.[32](#hsr2109-bib-0032){ref-type="ref"} The lack of a validation dataset was also a limitation. Additionally, we also cannot exclude response bias in the questionnaires.

5. CONCLUSION {#hsr2109-sec-0020}
=============

DL~PA~ is reduced in patients with chronic stage IV sarcoidosis compared with control subjects. Our findings implicate VO~2~max, which explains 13.3% of SPD, as significant influence on DL~PA~ in these patients. However, pulmonary function tests were insufficient to evaluate DL~PA~ in our study, and other parameters must be evaluated to understand all determinants of DL~PA~ in patients with chronic sarcoidosis. Future studies should also evaluate how DL~PA~ changes during and after pulmonary rehabilitation.
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